Mounjaro (tirzepatide) lowers blood sugar by activating two gut hormone receptors at once, something no other diabetes drug on the market does. It mimics both GIP and GLP-1, two hormones your body naturally releases after eating to signal your pancreas to produce insulin. This dual action produces larger drops in blood sugar and more weight loss than single-receptor drugs like Ozempic.
The Dual Hormone Approach
When you eat, your gut releases two key hormones: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both tell your pancreas to ramp up insulin production in response to rising blood sugar. In type 2 diabetes, this signaling system doesn’t work well enough on its own. Mounjaro steps in as a synthetic version of both hormones, binding to both receptors and amplifying the insulin response.
The drug isn’t a perfect copy of either natural hormone. It activates the GIP receptor with the same strength as your body’s own GIP, but at the GLP-1 receptor it behaves differently from natural GLP-1. This difference turns out to be an advantage: Mounjaro causes less receptor burnout at the GLP-1 receptor, meaning the signal stays effective longer rather than fading with repeated doses. Research from the PNAS shows this unique activation pattern likely contributes to why Mounjaro outperforms drugs that target GLP-1 alone.
GIP receptor activation also appears to improve how well your cells respond to insulin through a mechanism separate from weight loss. So the drug works on two fronts simultaneously: producing more insulin when blood sugar is high, and helping your body use that insulin more effectively.
What It Does Beyond Insulin
Mounjaro’s effects extend well past the pancreas. It slows down how quickly your stomach empties after a meal, which means glucose enters your bloodstream more gradually instead of in a sharp spike. This is one reason post-meal blood sugar readings improve so dramatically on the drug. The slower stomach emptying also makes you feel full sooner and stay full longer.
The drug also dials down glucagon, a hormone that tells your liver to release stored sugar into your blood. In type 2 diabetes, glucagon levels are often inappropriately high, pushing blood sugar up even when it’s already elevated. Mounjaro’s GLP-1 activity suppresses this excess glucagon, reducing the amount of sugar your liver dumps between meals and overnight.
Appetite suppression is another major piece. Mounjaro acts on brain pathways that regulate hunger, reducing food intake in a way that feels natural rather than forced. This combination of slower digestion, reduced liver sugar output, better insulin production, and lower appetite creates a compounding effect that addresses multiple broken systems in type 2 diabetes at once.
How Much It Lowers Blood Sugar
Across the SURPASS clinical trial program, Mounjaro consistently reduced A1C (a measure of average blood sugar over roughly three months) more than every comparator it was tested against. The 15 mg dose proved the most effective of any injectable diabetes medication studied head to head. In a network analysis comparing it to semaglutide (Ozempic’s active ingredient), high-dose Mounjaro lowered A1C by an additional 0.39 percentage points beyond high-dose semaglutide, and 0.73 points beyond low-dose semaglutide. For context, a 0.5-point A1C reduction is considered clinically meaningful.
Many trial participants reached A1C levels below 7%, which is the standard treatment target, and a significant number hit levels below 5.7%, which falls in the non-diabetic range.
Weight Loss in Clinical Trials
Weight loss with Mounjaro is substantial for a diabetes medication. In the SURPASS trials, people with type 2 diabetes lost between 12 and 25 pounds over 40 to 52 weeks, depending on the dose and what other medications they were taking. When added to metformin alone, the 15 mg dose produced an average loss of 25 pounds at 40 weeks, compared to 13 pounds for Ozempic 1 mg in the same trial.
Even at the lowest therapeutic dose of 5 mg, weight loss ranged from 12 to 17 pounds across trials. By comparison, people on insulin comparators (long-acting insulins like glargine or degludec) typically gained about 4 pounds over the same period. This weight loss isn’t just cosmetic. Losing 5 to 10% of body weight meaningfully improves insulin resistance, blood pressure, and cholesterol in people with type 2 diabetes.
How It’s Dosed
Mounjaro is a once-weekly injection, given on the same day each week at any time of day, with or without food. Everyone starts at 2.5 mg for the first four weeks. This starting dose is specifically for letting your body adjust and isn’t expected to control blood sugar on its own.
After four weeks, the dose increases to 5 mg, which is the first therapeutic dose. From there, if you need better blood sugar control, your dose can go up by 2.5 mg increments every four weeks or longer, up to a maximum of 15 mg. The gradual increase helps minimize side effects, particularly nausea. Many people find adequate control at 5 or 10 mg and never need the highest dose.
Common Side Effects
Digestive symptoms are the most frequent side effects, and they follow a predictable pattern. In placebo-controlled trials, nausea affected 12% of people on the 5 mg dose, 15% on 10 mg, and 18% on 15 mg, compared to 4% on placebo. Diarrhea rates were 12 to 17% across doses (versus 9% for placebo), and vomiting occurred in 5 to 9% of people.
The important detail is timing: most nausea, vomiting, and diarrhea cluster during the dose-escalation phase and decrease over time. Eating smaller meals, avoiding high-fat foods, and not lying down right after eating can help. For most people, these symptoms are mild to moderate and don’t lead to stopping the medication.
Heart Health Signals
Early cardiovascular data looks promising. A large observational study published in JACC: Advances found that people taking Mounjaro had a 40% lower rate of a combined outcome of heart attack, stroke, and death compared to those on GLP-1 drugs alone. Heart attacks specifically were 41% lower, and all-cause mortality was 65% lower in the Mounjaro group. These are observational findings, not from a randomized trial designed to prove cardiovascular benefit, so they carry some uncertainty. A dedicated cardiovascular outcomes trial (SURPASS-CVOT) is underway to provide more definitive answers.
Where It Fits in Diabetes Treatment
The American Diabetes Association’s 2025 guidelines position Mounjaro as a preferred option over insulin for people with type 2 diabetes who don’t have insulin deficiency. For people already on insulin, the guidelines recommend adding Mounjaro (or another GLP-1 based drug) rather than simply increasing insulin doses, because the combination offers better blood sugar control with less weight gain and lower risk of dangerously low blood sugar episodes.
The guidelines also single out Mounjaro for people who have both type 2 diabetes and fatty liver disease, where it may offer liver-protective benefits beyond blood sugar control. One combination to avoid: taking Mounjaro alongside a DPP-4 inhibitor (drugs like sitagliptin or saxagliptin), since both work on similar pathways and the combination doesn’t add meaningful benefit.